Last mentioned: 18h ago
Phase I Trials
Anticipated start of first-in-human safety and dosage escalation studies.
IND Filing
Target window for filing an Investigational New Drug application with the FDA.
Pre-clinical Completion
Expected conclusion of animal model testing and toxicology reports.
Study Publication
Stanford University researchers publish findings on a multi-pathogen vaccine candidate.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
Researchers at Stanford University have unveiled a novel vaccine candidate designed to provide broad-spectrum protection against a variety of viral infections. This multi-pathogen approach marks a significant shift from traditional strain-specific immunizations toward a more resilient public health defense.
NG Biotech and partner Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic tests targeting Candida auris and Acinetobacter baumannii. These assays aim to provide near-instant identification of high-priority antimicrobial-resistant pathogens to improve hospital infection control.